Open AccessOral medications regarding their safety and efficacy in the management of patent ductus arteriosus
Author(s) -
Mehmet Yekta Öncel,
Ömer Erdeve
Publication year - 2016
Publication title -
world journal of clinical pediatrics
Language(s) - English
Resource type - Journals
ISSN - 2219-2808
DOI - 10.5409/wjcp.v5.i1.75
Subject(s) - medicine , ductus arteriosus , ibuprofen , adverse effect , perforation , side effect (computer science) , anesthesia , pharmacology , materials science , computer science , punching , metallurgy , programming language
Patent ductus arteriosus (PDA) is a common clinical condition in preterm infants which is inversely related to birth weight and gestational age. Cyclooxygenase inhibitors such as indomethacin and ibuprofen which block the prostaglandin conversion from arachidonic acid are the most commonly used drugs for ductal closure. This review focuses on the safety and efficacy oral medications in the management of PDA in preterm infants. Ibuprofen seems to be the first choice due to its higher safety profile, as it is associated with fewer gastrointestinal and renal side effects when compared to indomethacin. PDA closure rates are better with oral than with intravenous ibuprofen probably due to the pharmacokinetic of the drug. However, these medications were reported to be associated with several adverse including transient renal failure, gastrointestinal bleeding and perforation, hyperbilirubinemia and platelet dysfunction. Paracetamol seems be an alternative to PDA therapy with lower adverse events and side effects.